Floatz logo

TACROLIMUS

Liver Transplant Disorder

Thomas Jefferson UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Liver Transplant Disorder cohort.

Asset / SponsorPhaseRating
Enteric-Coated Mycophenolic Acid
Thomas Jefferson University
Phase 4BB
Basiliximab
Thomas Jefferson University
Phase 4BB
PREDNISONE TABLETS
Thomas Jefferson University
Phase 4BB
Benadryl
Elizabeth C. Verna
Phase 1CC
Solu-Cortef
Elizabeth C. Verna
Phase 1CC
Siplizumab
Elizabeth C. Verna
Phase 1C

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →